BRPI0515533B8 - formulação farmacêutica estável para inibir urocinase - Google Patents
formulação farmacêutica estável para inibir urocinaseInfo
- Publication number
- BRPI0515533B8 BRPI0515533B8 BRPI0515533A BRPI0515533A BRPI0515533B8 BR PI0515533 B8 BRPI0515533 B8 BR PI0515533B8 BR PI0515533 A BRPI0515533 A BR PI0515533A BR PI0515533 A BRPI0515533 A BR PI0515533A BR PI0515533 B8 BRPI0515533 B8 BR PI0515533B8
- Authority
- BR
- Brazil
- Prior art keywords
- stable pharmaceutical
- pharmaceutical formulation
- inhibit urokinase
- urokinase
- inhibit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004045720.4 | 2004-09-21 | ||
DE102004045720A DE102004045720A1 (de) | 2004-09-21 | 2004-09-21 | Stabile Dosierungsform von Phenylalanin-Derivaten |
PCT/EP2005/010143 WO2006032461A1 (de) | 2004-09-21 | 2005-09-20 | Stabile dosierungsform von phenylalanin-derivaten |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0515533A BRPI0515533A (pt) | 2008-07-29 |
BRPI0515533B1 BRPI0515533B1 (pt) | 2020-12-08 |
BRPI0515533B8 true BRPI0515533B8 (pt) | 2021-05-25 |
Family
ID=35429536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515533A BRPI0515533B8 (pt) | 2004-09-21 | 2005-09-20 | formulação farmacêutica estável para inibir urocinase |
Country Status (14)
Country | Link |
---|---|
US (1) | US9089532B2 (pt) |
EP (1) | EP1799265B1 (pt) |
JP (1) | JP5054529B2 (pt) |
KR (1) | KR101228385B1 (pt) |
CN (1) | CN1993144B (pt) |
AT (1) | ATE480260T1 (pt) |
AU (1) | AU2005287582B2 (pt) |
BR (1) | BRPI0515533B8 (pt) |
CA (1) | CA2580639C (pt) |
DE (2) | DE102004045720A1 (pt) |
ES (1) | ES2347670T3 (pt) |
MX (1) | MX2007000399A (pt) |
RU (1) | RU2358736C2 (pt) |
WO (1) | WO2006032461A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004057195A1 (de) | 2004-11-26 | 2006-06-01 | Wilex Ag | Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon |
US11045453B1 (en) | 2020-03-10 | 2021-06-29 | Redhill Biopharma Ltd. | Serine protease inhibitor for treating coronavirus infection |
US11471448B2 (en) | 2020-12-15 | 2022-10-18 | Redhill Biopharma Ltd. | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA986594B (en) * | 1997-07-25 | 1999-01-27 | Abbott Lab | Urokinase inhibitors |
DE59903981D1 (de) * | 1998-07-20 | 2003-02-13 | Wilex Ag | Neue urokinase-inhibitoren |
AU2002352245B2 (en) * | 2001-12-12 | 2008-10-16 | Wilex Ag | Selective arylguanidine peptides as urokinase inhibitors |
ATE399175T1 (de) * | 2002-03-11 | 2008-07-15 | Curacyte Ag | Hemmstoffe der urokinase, ihre herstellung und verwendung |
DE10225876A1 (de) * | 2002-06-11 | 2003-12-24 | Wilex Ag | Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren |
AU2003253326A1 (en) * | 2002-07-25 | 2004-02-16 | Wilex Ag | Method for the production of phenylalanine derivatives |
DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
-
2004
- 2004-09-21 DE DE102004045720A patent/DE102004045720A1/de not_active Withdrawn
-
2005
- 2005-09-20 AT AT05786251T patent/ATE480260T1/de not_active IP Right Cessation
- 2005-09-20 AU AU2005287582A patent/AU2005287582B2/en not_active Ceased
- 2005-09-20 US US11/631,891 patent/US9089532B2/en active Active
- 2005-09-20 ES ES05786251T patent/ES2347670T3/es active Active
- 2005-09-20 WO PCT/EP2005/010143 patent/WO2006032461A1/de active Application Filing
- 2005-09-20 DE DE502005010237T patent/DE502005010237D1/de active Active
- 2005-09-20 BR BRPI0515533A patent/BRPI0515533B8/pt not_active IP Right Cessation
- 2005-09-20 MX MX2007000399A patent/MX2007000399A/es active IP Right Grant
- 2005-09-20 EP EP05786251A patent/EP1799265B1/de not_active Not-in-force
- 2005-09-20 KR KR1020077005447A patent/KR101228385B1/ko active IP Right Grant
- 2005-09-20 RU RU2007115064/15A patent/RU2358736C2/ru active
- 2005-09-20 JP JP2007532821A patent/JP5054529B2/ja not_active Expired - Fee Related
- 2005-09-20 CN CN2005800256252A patent/CN1993144B/zh active Active
- 2005-09-20 CA CA2580639A patent/CA2580639C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2358736C2 (ru) | 2009-06-20 |
EP1799265B1 (de) | 2010-09-08 |
RU2007115064A (ru) | 2008-10-27 |
US20070244127A1 (en) | 2007-10-18 |
CN1993144B (zh) | 2012-05-30 |
ATE480260T1 (de) | 2010-09-15 |
JP2008513529A (ja) | 2008-05-01 |
AU2005287582B2 (en) | 2010-08-19 |
WO2006032461A1 (de) | 2006-03-30 |
BRPI0515533B1 (pt) | 2020-12-08 |
JP5054529B2 (ja) | 2012-10-24 |
MX2007000399A (es) | 2008-03-11 |
KR101228385B1 (ko) | 2013-02-04 |
US9089532B2 (en) | 2015-07-28 |
BRPI0515533A (pt) | 2008-07-29 |
AU2005287582A1 (en) | 2006-03-30 |
CN1993144A (zh) | 2007-07-04 |
KR20070054197A (ko) | 2007-05-28 |
DE102004045720A1 (de) | 2006-03-23 |
DE502005010237D1 (de) | 2010-10-21 |
EP1799265A1 (de) | 2007-06-27 |
ES2347670T3 (es) | 2010-11-03 |
CA2580639C (en) | 2013-04-23 |
CA2580639A1 (en) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2023022I1 (no) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
CY1113192T1 (el) | Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora | |
CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
EP2321264A4 (en) | DEACETYLASEINHIBITORS AND APPLICATIONS THEREOF | |
EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
SE0301700D0 (sv) | Novel compounds | |
ECSP077238A (es) | Composiciones para entrega de drogas altamente solubles en agua | |
EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
MY154898A (en) | P70 s6 kinase inhibitors | |
DK1791830T3 (da) | Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer | |
EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
ATE439355T1 (de) | 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren | |
DK1641803T3 (da) | Thienopyrimidinderivater som kaliumkanalinhibitorer | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
ATE502935T1 (de) | C-met-proteinkinasehemmer | |
BRPI0515533B8 (pt) | formulação farmacêutica estável para inibir urocinase | |
MX2008008470A (es) | Nuevos derivados pirrolicos con actividad inhibidora de desacetilasa de histonas. | |
IL191670A0 (en) | Compounds for the inhibition of apoptosis | |
MX2009011576A (es) | Nuevos derivados de 4,8-difenil-poliazanaftaleno. | |
ATE312610T1 (de) | Liposomale formulierungen von phenylalanin- derivaten | |
DK1962822T3 (da) | Terapi af maligne neoplasier | |
UA96742C2 (en) | Mek inhibitors and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: WILEX AG (DE) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2740 DE 11-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |